Find Out More Since 1999, Celadon Laboratories, Inc. has focused on developing the best software available for selected life sciences applications. Founded by Dr. Raymond J. Peterson, the company has evolved from its initial focus on genomics software, to becoming a broader-based developer of immunoassay analysis and quality-control software and associated applications. Celadon is also a research and service provider in the areas of clinical genomics and modified nucleic acid chemistries.
Our newest product is ImmūnQC™ QA/QC software for immunoassay development, which we have created with the singular focus on the idea that good software can organize and simplify lab processes, and that most manual or unautomated processes can be converted to effective algorithms that help our customers’ clinics, labs, or manufacturing facilities operate as efficiently as possible. Our company’s software products are delivered in the cloud by subscription, or in some cases installed on our customer’s server. Celadon’s cloud software and science expertise, together with its advanced technologies in several key areas, have put the company in a prime position for expansion into the personal healthcare services market.
Celadon’s products have been developed under contract to and in cooperation with several U.S. federal agencies – the National Cancer Institute, the Air Force, the Army, and the Centers for Disease Control and Prevention. ImmūnQC™ had its origins in a U.S. Air Force contact under which the Company developed software for the analysis of a new type of tuberculin test.
Raymond J. Peterson, Ph.D.
Chairman & Chief Scientific Officer
Dr. Peterson has driven Celadon’s scientific and technical innovations since founding the Company in 1999. As a scientist whose background has integrated his understanding of the biotechnology industry with commercially-focused research and product development experience, he has led the development of software that responds to the industry need for accuracy, efficiency, and selling biotech products.
As an award-winning researcher at NIH and NCI, Dr. Peterson recognized the need for commercial software that would free academic and industry researchers from the laborious and inefficient task of designing genomic assays. He founded Celadon with that original purpose, and in the decade-and-a-half since the company’s founding, he has helped lead the company into related areas of software development.
Dr. Peterson has been the principal investigator on seven state, federal, and private non-profit grants and research contracts. He has won research awards from the National Institute on Alcohol Abuse and Alcoholism; the National Cancer Institute, and the National Institutes of Health. He has a B.S. in Management from the University of Pennsylvania’s Wharton School and a Ph.D in in Biological Anthropology from Pennsylvania State University.
Lawrence A. Kessner
Chief Executive Officer
Mr. Kessner’s background in business ventures including media, law, and public-private enterprise has informed his approach to building a biotech company. Since he joined Raymond Peterson as a principle in and CEO of Celadon in 2000, he has worked on product development, and formation of industry and academic partnerships, that are responsive to the growing and ever-changing needs of the biotech industry.
He has focused on the company’s strategic, sales, marketing, and legal issues, and has worked closely with industry customers and government agencies to deliver the best results. Mr. Kessner’s experience as a writer and attorney, combined with Celadon’s scientific expertise, has helped Celadon win, negotiate, and manage contracts with government agencies and commercial entities.
Prior to joining Celadon, Mr. Kessner founded or managed several early-stage enterprises since 1990, including a group of radio stations, a children’s museum built in partnership with the Walt Disney Company, and an online legal-information business. He was a reporter at the Baltimore Sun, and later the first publisher of Baltimoresun.com. He also was an attorney in private practice in Washington, D.C. He received a B.A. in Philosophy from Johns Hopkins and a law degree from Georgetown.
Jason Kahn, Ph.D.
Jason Kahn is Associate Professor in the Department of Chemistry and Biochemistry at the University of Maryland College Park. He has 21 years of experience in DNA structure and topology; construction of nano-scale objects using DNA; and application of biophysical methods and computer simulation to complex systems. Dr. Kahn received his A.B. from Harvard and Ph.D. from Berkeley.
David H. Mathews, M.D., Ph.D.
Professor of Biochemistry and Chemistry at the University of Rochester. Dr. Mathews’ work has been instrumental in helping Celadon’s software better predict the role and impact of folding and cross hybridization of primers and probes. His work spans the fields of Computational Biology and Bioinformatics. His research focuses on predicting nucleic acid structure, developing computational tools for targeting RNA with pharmaceuticals, and using RNA as a pharmaceutical. Dr. Mathews has refined algorithms that predict folding and cross hybridization.
David M. Rocke, Ph.D.
David Rocke is Distinguished Professor of Biostatistics in the Department of Public Health Sciences at the University of California, Davis. He is a member of the UC Davis Genome Center, the UC Davis Cancer Center, and Co-Director of the Institute for Data Analysis and Visualization. A Fellow of the Royal Statistical Society, the American Statistical Association, and the American Association for the Advancement of Science, Dr. Rocke since 1996 has consulted with Celadon on statistical issues in connection with the Company’s development of its Immunoassay analysis platform.
Stewart Friedman, Ph.D.
Stew Friedman is Practice Professor of Management at the University of Pennsylvania’s Wharton School of Management. He has been on the Wharton faculty since 1984, and was founding director of the Wharton Leadership Program. He is also founding director of Wharton’s Work/Life Integration Project. Dr. Friedman’s award-winning book, Total Leadership: Be a Better Leader, Have a Richer Life (Harvard Business Press, 2008) describes a program which used by companies worldwide, including as a primary intervention in a multi-year study, funded by the National Institutes of Health, on improving the careers and lives of women in medicine. Stew has also served as a senior executive at Ford Motor Company, where he was director of the company’s renowned Leadership Development Center.
Marc Beal, M.B.A.
Marc is Director of Corporate Development at Biosearch Technologies, Inc., one on Celadon’s earliest customers. At Biosearch. he is charged with seeking new business opportunities for the company, and also is involved in establishing and managing sales, marketing, international distribution channels/partners for the company’s products, determining new markets and applications for company products, and negotiating licensing and supply agreements. Marc is a former National Sales Manager at Biosource/Invitrogen, and was a Senior Development Scientist at Merck KGaA, as well as a research scientist at Genentech.
Celadon’s customers have ranged from large U.S. Government Agencies to international corporations to start-ups. What they have in common is that all have had successful engagements with Celadon, and all projects have been completed on time and on budget. Customers have included: